SOLASIA PHARMA K.K. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26 JPY | +4.00% |
|
+4.00% | -42.22% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 21,428 | 14,226 | 14,285 | 8,230 | 7,579 | 4,734 | - | - |
| Enterprise Value (EV) 1 | 17,380 | 12,322 | 13,655 | 7,464 | 6,911 | 4,573 | 5,361 | 5,215 |
| P/E ratio | -10.4 x | -3.3 x | -5.62 x | -2.92 x | -6.8 x | -8.4 x | -5.75 x | 50 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 16.4 x | 31.3 x | 25.6 x | 7.54 x | 12.3 x | 2.86 x | 2.76 x | 1.67 x |
| EV / Revenue | 13.3 x | 27.1 x | 24.4 x | 6.84 x | 11.2 x | 2.76 x | 3.12 x | 1.84 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | -3 x | - | -8.41 x | -5.72 x | 36.7 x |
| FCF Yield | - | - | - | -33.4% | - | -11.9% | -17.5% | 2.72% |
| Price to Book | 3.1 x | 3.9 x | 5.52 x | 3.09 x | 4.17 x | - | - | - |
| Nbr of stocks (in thousands) | 116,455 | 122,641 | 133,506 | 167,966 | 168,428 | 182,058 | - | - |
| Reference price 2 | 184.0 | 116.0 | 107.0 | 49.00 | 45.00 | 26.00 | 26.00 | 26.00 |
| Announcement Date | 2/13/20 | 2/10/21 | 2/9/22 | 2/14/23 | 2/14/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,310 | 454 | 559 | 1,092 | 617 | 1,657 | 1,717 | 2,829 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -1,762 | -4,116 | -2,419 | -2,470 | -1,139 | -543 | -931 | 101 |
| Operating Margin | -134.5% | -906.61% | -432.74% | -226.19% | -184.6% | -32.77% | -54.22% | 3.57% |
| Earnings before Tax (EBT) 1 | -1,797 | -4,159 | -2,442 | -2,492 | -1,135 | -538 | -926 | 106 |
| Net income 1 | -1,867 | -4,127 | -2,478 | -2,548 | -1,112 | -538 | -926 | 96 |
| Net margin | -142.52% | -909.03% | -443.29% | -233.33% | -180.23% | -32.47% | -53.93% | 3.39% |
| EPS 2 | -17.75 | -35.16 | -19.04 | -16.77 | -6.620 | -3.094 | -4.522 | 0.5200 |
| Free Cash Flow 1 | - | - | - | -2,492 | - | -544 | -937 | 142 |
| FCF margin | - | - | - | -228.21% | - | -32.83% | -54.57% | 5.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 147.92% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/10/21 | 2/9/22 | 2/14/23 | 2/14/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q3 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 240 | - | 278 | 5 | 113 | 189 | 296 | 220 | 529 | 73 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1,268 | - | -1,362 | -701 | -600 | -1,228 | -724 | -245 | -462 | -325 |
| Operating Margin | -528.33% | - | -489.93% | -14,020% | -530.97% | -649.74% | -244.59% | -111.36% | -87.33% | -445.21% |
| Earnings before Tax (EBT) 1 | -1,283 | - | -1,383 | -701 | -606 | -1,233 | -740 | -247 | -450 | -334 |
| Net income 1 | -1,272 | - | -1,394 | -717 | -615 | -1,247 | -802 | -241 | -437 | -331 |
| Net margin | -530% | - | -501.44% | -14,340% | -544.25% | -659.79% | -270.95% | -109.55% | -82.61% | -453.42% |
| EPS 2 | -10.93 | - | -10.91 | -5.450 | -4.610 | -8.980 | -5.000 | -1.440 | -2.610 | -1.960 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/12/20 | 2/10/21 | 8/11/21 | 11/10/21 | 5/13/22 | 8/15/22 | 11/14/22 | 5/15/23 | 8/10/23 | 11/13/23 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 627 | 481 |
| Net Cash position 1 | 4,048 | 1,904 | 630 | 766 | 668 | 161 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -2,492 | - | -544 | -937 | 142 |
| ROE (net income / shareholders' equity) | -26.7% | -78.1% | -79.4% | -97.1% | -49% | - | - | - |
| ROA (Net income/ Total Assets) | -22.9% | -60.6% | -54.8% | -79.4% | -42.3% | - | - | - |
| Assets 1 | 8,142 | 6,808 | 4,525 | 3,210 | 2,627 | - | - | - |
| Book Value Per Share | 59.40 | 29.80 | 19.40 | 15.90 | 10.80 | - | - | - |
| Cash Flow per Share | -13.20 | -30.90 | -15.20 | -13.30 | -3.640 | - | - | - |
| Capex 1 | - | - | - | 418 | - | 33 | 34 | 57 |
| Capex / Sales | - | - | - | 38.28% | - | 1.99% | 1.98% | 2.01% |
| Announcement Date | 2/13/20 | 2/10/21 | 2/9/22 | 2/14/23 | 2/14/24 | - | - | - |
1JPY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
26
JPY
Average target price
100
JPY
Spread / Average Target
+284.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.22% | 30.07M | |
| -4.51% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 4597 Stock
- Financials Solasia Pharma K.K.
